← Leaderboards
Judith Villablanca
University Of Southern California
$191,317
Attributed
$191,317
Total exposure
1
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$191,317 · 1
By mechanism
M01$191,317 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Southern California
Same institution · by research overlap
- Caryn Lerman$95,133,528
- Robert C Seeger$12,536,093
- Arthur W Toga$135,966,223
- Thomas A Buchanan$121,360,154
- Heinz Josef Lenz$20,123,312
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchClinical Trial Phase IFenretinideHuman SubjectHuman Therapy EvaluationNeoplasm /Cancer ChemotherapyNeuroblastomaPediatric Neoplasm /Cancer
Grant awards (5)
PHASE 1 STUDY OF FENRETINIDE IN CHILDREN W/ HIGH RISK SOLID TUMORS$0
M01 · FY2002 · RR
PHASE 1 STUDY OF FENRETINIDE IN CHILDREN W/ HIGH RISK SOLID TUMORS$155,764
M01 · FY2001 · RR
PHASE 1 STUDY OF FENRETINIDE IN CHILDREN W/ HIGH RISK SOLID TUMORS$0
M01 · FY2001 · RR
PHASE 1 STUDY OF FENRETINIDE IN CHILDREN W/ HIGH RISK SOLID TUMORS$35,553
M01 · FY2000 · RR
PHASE 1 STUDY OF FENRETINIDE IN CHILDREN W/ HIGH RISK SOLID TUMORS$0
M01 · FY2000 · RR